NEXT Life Sciences Announces Successful Plan A™ Delivery Device Clinical Trial in Australia
Australian Clinical Results Demonstrate 100% Success Rate for New Delivery Method
Results Demonstrate the Effectiveness of a Revolutionary Male Contraceptive Delivery System
Plan A™ is designed to offer men the first non-hormonal, long-acting, and on-demand reversible birth control. This innovative contraceptive uses a proprietary hydrogel, Vasalgel®, designed to filter out sperm for up to 10 years, and can be quickly administered by a medical professional in a variety of settings—not just clinics or hospitals. The proprietary access method tested in this Australian trial would allow for a confirmation that the hydrogel can be held in place, while also being less invasive than traditional methods, such as syringes or needles. Doctors have now successfully used the new delivery method introduced by Plan A™ in procedures involving 27 men.
“Contraception has been lacking innovation for decades; we at NEXT Life Sciences are excited to continue to bring Plan A™ closer to fruition so men and couples can select from a variety of birth control options that best suit their lifestyles,” said Dr. Darlene R. Walley, Chief Executive Officer of NEXT Life Sciences. “Our clinical trials in Canada and Australia validate our approach while bringing us closer to further clinical trials and market launch.”
NEXT Life Sciences has also announced it is in the process of its Series A raise to complete clinical trials. This follows prior oversubscribed funding of $10 million and the Male Contraceptive Initiative’s reaffirmation of its commitment to Plan A™ with a renewed grant.
“Plan A™ has the potential to be a game-changer for men and couples as they traverse their lives and careers, giving them an on-demand reversible contraception option,” said Founder and Executive Chairman L.R. Fox. “This is one of the reproductive health innovations NEXT Life Sciences plans to bring to market to revolutionize a critical area of health.”
For more information, visit https://www.nextlifesciences.org/ and https://www.planaformen.com/.
About NEXT Life Sciences
NEXT Life Sciences, Inc. (NEXT) is modernizing reproductive healthcare with its flagship product, Plan A™, a non-hormonal, long-lasting, and reversible male contraceptive. NEXT’s executive management team and board members have proven track records of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status.
Disclaimer
All forward-looking statements are not guarantees of future performance, and undue reliance should not be placed on them. Statements within this document have not been evaluated by the Food and Drug Administration. Plan A™ is currently not approved by the FDA for commercial distribution.
NEXT Life Sciences
Plan A™ Male Birth Control
+1 209-870-6398
press@nextlifesciences.org
Visit us on social media:
Facebook
X
LinkedIn
Instagram
TikTok
Other
Distribution channels: Business & Economy, Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry, Human Rights, Science
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release